Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.57 |
| ▸ | KRAS | P01116 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17237268 | 1.00 | TUBB1 (0.57) | TUBB1KRASALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL17236633 | 0.96 | TUBB1 (0.57) | TUBB1KRASALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL17236634 | 0.96 | TUBB1 (0.57) | TUBB1KRASALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL17236822 | 0.94 | TUBB1 (0.58) | TUBB1KRASALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL17236819 | 0.94 | TUBB1 (0.58) | TUBB1KRASALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL17237122 | 0.92 | ABCG2 (0.54) | TUBB1KRASALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL17237126 | 0.92 | ABCG2 (0.54) | TUBB1KRASALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL17236702 | 0.92 | TUBB1 (0.56) | TUBB1KRASALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL17236705 | 0.92 | TUBB1 (0.56) | TUBB1KRASALDH1A1ATMSMN1; SMN2 | |
| SCHEMBL17237301 | 0.92 | TUBB1 (0.60) | TUBB1KRASALDH1A1ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2942345-B1 | 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES FOR THE TREATMENT OF CANCER | COUNCIL SCIENT IND RES (IN) | 2018-03-28 | — | — | EP | claimed |
| US-9487482-B2 | 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-11-08 | — | — | US | claimed |
| US-20150322009-A1 | NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-11-12 | — | — | US | claimed |
| EP-2942345-A1 | 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES for the treatment of cancer | Council of Scientific and Industrial Research (IN) | 2015-11-11 | — | — | EP | claimed |
| EP-2942345-B1 | 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES FOR THE TREATMENT OF CANCER | COUNCIL SCIENT IND RES (IN) | 2018-03-28 | — | — | EP | disclosed |
| EP-2942345-B1 | 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES FOR THE TREATMENT OF CANCER | COUNCIL SCIENT IND RES (IN) | 2018-03-28 | — | — | EP | disclosed |
| US-9487482-B2 | 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-11-08 | — | — | US | disclosed |
| US-9487482-B2 | 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-11-08 | — | — | US | disclosed |
| US-9487482-B2 | 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-11-08 | — | — | US | disclosed |
| US-20150322009-A1 | NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-11-12 | — | — | US | disclosed |
| US-20150322009-A1 | NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-11-12 | — | — | US | disclosed |
| US-20150322009-A1 | NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2015-11-12 | — | — | US | disclosed |
| EP-2942345-A1 | 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES for the treatment of cancer | Council of Scientific and Industrial Research (IN) | 2015-11-11 | — | — | EP | disclosed |
| EP-2942345-A1 | 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES for the treatment of cancer | Council of Scientific and Industrial Research (IN) | 2015-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322009-A1 | NOVEL 3,4,5-TRIMETHOXYSTYRYLARYLAMINOPROPENONES AS POTENTIAL ANTICANCER AGENTS | MCL1, HCCS, CASP3 | TUBB1 853/4885KRAS 528/4885ALDH1A1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.